Morten Blinkenberg
Overview
Explore the profile of Morten Blinkenberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
419
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Boesen M, Langkilde A, Ilginiene J, Magyari M, Blinkenberg M
Mult Scler Relat Disord
. 2021 Dec;
57:103443.
PMID: 34942545
Background: MRI allows demonstration of dissemination in space and time at the first demyelinating event. However, no pediatric MS study has investigated the validity of MS-specific outcomes described in MRI...
12.
Uccelli A, Laroni A, Ali R, Battaglia M, Blinkenberg M, Brundin L, et al.
Lancet Neurol
. 2021 Oct;
20(11):917-929.
PMID: 34687636
Background: Mesenchymal stem cells (MSCs), also known as mesenchymal stromal cells, have been proposed as a promising therapeutic option for people with multiple sclerosis on the basis of their immunomodulatory...
13.
Pontieri L, Blinkenberg M, Bramow S, Papp V, Rasmussen P, Kant M, et al.
Eur J Neurol
. 2021 Oct;
29(2):496-504.
PMID: 34644452
Background And Purpose: Real-world evidence regarding the effectiveness and safety of ocrelizumab for the treatment of multiple sclerosis (MS) is limited. The aim was to evaluate the effectiveness and safety...
14.
Hojsgaard Chow H, Talbot J, Lundell H, Madsen C, Marstrand L, Lange T, et al.
Neurol Neuroimmunol Neuroinflamm
. 2021 Aug;
8(5).
PMID: 34429340
Background And Objective: To study whether dimethyl fumarate is superior to placebo in decreasing CSF concentrations of neurofilament light chain (NFL) in patients with primary progressive MS (PPMS). Methods: In...
15.
Boesen M, Blinkenberg M, Born A, Magyari M, Chitnis T, Thygesen L, et al.
Mult Scler Relat Disord
. 2020 Dec;
46:102590.
PMID: 33296986
Background: It is essential to distinguish acute disseminated encephalomyelitis (ADEM) from MS early. Our aim was to determine MRI features at baseline and follow-up to distinguish pediatric ADEM from MS...
16.
Boesen M, Blinkenberg M, Thygesen L, Eriksson F, Magyari M
Mult Scler
. 2020 Sep;
27(2):259-267.
PMID: 32975459
Background: Pediatric multiple sclerosis (MS) may hamper educational achievements due to psychiatric comorbidity and cognitive impairment. Our aims were to investigate school performance, psychiatric comorbidity, and healthcare utilization following pediatric...
17.
Andersen K, Lasic S, Lundell H, Nilsson M, Topgaard D, Sellebjerg F, et al.
Brain Commun
. 2020 Sep;
2(2):fcaa077.
PMID: 32954329
Multiple sclerosis leads to diffuse damage of the central nervous system, affecting also the normal-appearing white matter. Demyelination and axonal degeneration reduce regional fractional anisotropy in normal-appearing white matter, which...
18.
Bauer C, Dyrby T, Sellebjerg F, Madsen K, Svolgaard O, Blinkenberg M, et al.
Neuroimage Clin
. 2020 Sep;
28:102393.
PMID: 32916467
Multiple Sclerosis (MS) is characterized by demyelination and neurodegeneration of the central nervous system and causes excessive fatigue in more than 80% of the patients. The pathophysiologic mechanisms causing fatigue...
19.
Kopp T, Blinkenberg M, Petersen T, Soelberg Sorensen P, Magyari M
Mult Scler Relat Disord
. 2020 Feb;
40:101956.
PMID: 32007654
Background: A consensus of early treatment with disease-modifying therapies (DMT) in multiple sclerosis (MS) has been reached based on several observational and experimental studies in adults. However, paediatric onset (PO)MS...
20.
Sellebjerg F, Blinkenberg M, Soelberg Sorensen P
CNS Drugs
. 2020 Jan;
34(3):269-280.
PMID: 31994023
Multiple sclerosis (MS) was previously thought to be a T-cell-mediated, demyelinating disease of the central nervous system. Disease-modifying therapies targeting T cells have, indeed, shown remarkable efficacy in patients with...